Stock Market Midday, Aug. 25: Tech Stocks Rebound and Dick's Sporting Goods Plummets 27%

U.S. stocks rose modestly in early trading (Nasdaq +0.58%, S&P 500 +0.23%, Dow +0.07%) as the 10-year Treasury yield fell 0.07% to 4.64%, easing rate pressure. The tape was mixed at the stock level—Moderna surged >12% on positive personalized cancer vaccine trial results, while Dick’s Sporting Goods dropped >27% after earnings. Bitcoin broke above $80,000 for the first time in three months on a Treasury-expanded bond-buyback announcement, but escalating U.S.-Canada tariff tensions remain a key overhang. Investors are also looking ahead to Nvidia earnings and the Fed Chair’s Jackson Hole speech for clearer signals on AI demand and potential rate changes.

Analysis

The rate move matters more than the index tape: a softer 10Y reduces the discount-rate headwind on long-duration growth, which is why semis and crypto proxies can outpace even if the macro headline flow is noisy. That is still a fragile setup; if yields stop easing or Jackson Hole pushes back on easing expectations, the same names with the highest multiple sensitivity will de-rate fastest. In that regime, the market will likely rotate from beta-chasing into cash-flow durability.

The cleanest loser is discretionary retail with tariff exposure and weak pricing power. A post-earnings air pocket in a name like DKS often becomes a 1-2 month underperformance story because the damage is not just near-term demand, but inventory and promo cadence that can pressure margins for several quarters. Any further softening in consumer spending would spill over to mall-adjacent peers and sporting-goods suppliers before it shows up in the broader retail index.

For MRNA, the market is paying for optionality, not cash flow, so the move is more about probability-weighted pipeline rerating than immediate earnings power. The contrarian miss is that investors are bundling three different trades together — lower yields, AI upside, and crypto liquidity — when those catalysts have different failure points and time horizons. The highest conviction expression is relative value, not blanket risk-on; NVDA can validate the AI capex cycle, but one downside surprise would likely hit AMD and high-beta semiconductor multiples harder than the market is pricing today.

Key Decisions for Investors

• Long AMD / short INTC for 1-3 months as a relative-value AI exposure: AMD has better operating leverage to a strong NVDA read-through, while INTC remains more execution- and balance-sheet-sensitive. Falsify if NVDA guides AI demand lower or if AMD management undercuts the follow-through.
• Buy a limited-risk NVDA call spread into earnings rather than stock if you want event exposure; the setup is a volatility trade on AI demand, not a clean directional macro call. Exit if the guide is merely in-line and the stock fails to hold its post-print gap.
• Short DKS on any relief bounce over the next 2-6 weeks, or use a put spread, on the view that the market is underestimating margin bleed from promotions and tariff-linked input costs. Cover if management raises guidance or sequential comps re-accelerate.
• Long COIN or HOOD only if BTC holds above 80k for several sessions; this is a momentum/liquidity trade with a short fuse, not a fundamental re-rating. Reverse if BTC loses 75k or if Treasury buyback-driven risk appetite fades.
• No chase on MRNA after the spike; treat it as a de-risking event and wait for confirmation on clinical durability before adding capital. The commercial payoff is measured in years, so the trade is only attractive on pullbacks or if the next data step materially expands addressable value.